Last updated 2026-07-20
- Raised $3.3M Series A led by Entrée Capital, Oct 2024
- Raised Seed round led by aMoon Fund, Sep 2021
Total raised
$3.3M
Last: Undisclosed Round 2024-11
Stage
Seed
Founded
2021
Headcount
8
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
caVos Biotherapeutics is an Israeli biotech company that leverages comparative genomics and AI to uncover novel mRNA therapeutics targeting longevity-related indications such as fibrosis, tissue regeneration, and cancer. The company has developed a proprietary evolutionary intelligence platform and a cross-species genomic atlas to identify naturally optimized genetic variants linked to longevity and regeneration across the animal kingdom. By translating these insights into new, precise, and safe drugs, caVos Biotherapeutics aims to revolutionize therapeutic discovery for age-related diseases.
Funding history · 2 rounds · $3.3M total
2024-10
A Round
$3.3M
★ Entrée CapitalNFX CapitalTal VenturesAlumni VenturesIsrael Innovation Authority
2021-09
Seed
Undisclosed
★ aMoon Fund
Headcount over time
From 6 (2022-11) to 9 (2026-01) · +3 (+50%) · 7 points · source: Finder history + radar grounding
Q&A
- What is caVos Biotherapeutics' primary focus?
- caVos Biotherapeutics is developing novel anti-cancer drugs by using a multi-level genomic algorithm to uncover the genetic basis of cancer resistance found in animals.
- When was caVos Biotherapeutics founded?
- caVos Biotherapeutics was founded in April 2021.
- How many employees does caVos Biotherapeutics currently have?
- caVos Biotherapeutics has 1-10 employees.
- What is the total amount of funding caVos Biotherapeutics has raised to date?
- caVos Biotherapeutics has raised a total of $3,300,000 USD.
- When was caVos Biotherapeutics' most recent funding round, and who were the lead investors?
- caVos Biotherapeutics' most recent funding round was in November 2024, with Entrée Capital as a lead investor.
- What is caVos Biotherapeutics' current funding stage?
- caVos Biotherapeutics is currently in the Seed funding stage.
- What sector does caVos Biotherapeutics primarily operate in?
- caVos Biotherapeutics primarily operates in the Health Tech & Life Sciences sector.
- What technologies does caVos Biotherapeutics utilize in its work?
- caVos Biotherapeutics utilizes Biologicals and Genes technologies.
Team · 2
Yuval Tabach
Founder · Founder, Professor of Genomics, Evolution, and Data Science
Haim Belinson
Founder · CEO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
Verified
Tags
genomicscancer-researchdrug-discoverypharmaceuticalsdrug-developmentcancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cavosbio.com/ |
|---|---|
| linkedin.com/company/78737148 |
Identifiers & details
| Founded | 2021-4 |
|---|---|
| Employees (exact) | 8 |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516373156 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2021-04-07 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 3 — shares_capital (1), annual_report (2) |
| Registered address | ספיר פנחס 3 נס ציונה |
Recent registry events
| Date | Event |
|---|---|
| 2025-09-28 | הקצאת מניות |
| 2025-07-24 | דו~ח שנתי-הוספת דירקטור |
| 2025-07-24 | דו~ח שנתי-הקצאת מניות |